MOL# 29223

**Identification of Leu276 of the S1P₁ receptor and Phe263 of the S1P₃ Receptor in
Interaction with Receptor Specific Agonists by Molecular Modeling,
Site-Directed Mutagenesis and Affinity Studies**

Qiaolin Deng, Joseph A. Clemas, Gary Chrebet, Paul Fischer, Jeffrey J. Hale, Zhen Li, Sander G. Mills,
James Bergstrom², Suzanne Mandala, Ralph Mosley and Stephen A. Parent¹

Department of Molecular Systems (Q.D., R.M.), Department of Immunology & Rheumatology (J.A.C.,
G.C., J.B., S.M. S.A.P.), Department of Cardiovascular Diseases (P.F.), and Department of Medicinal
Chemistry (J.J.H., Z.L., S.G.M.), Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065,
USA

MOL# 29223

Running title: Residues Important for S1P₁/S1P₃ Agonist Selectivity

Corresponding Author: Dr. Stephen A. Parent

Merck Research Laboratories

P.O. Box 2000, RY80Y-225

Rahway, NJ 07065, USA

Phone: (732) 594-5787

Fax: (732) 594-1399

Email: steve_parent@merck.com

Text pages: 36

Tables: 3

Figures: 8

References: 45

Abstract words: 190

Introduction words: 740

Discussion words: 1544

Abbreviations: GPCR, G protein-coupled receptor; Edg, endothelial differentiation gene; S1P, sphingosine-1-phosphate; LPA, lysophosphatidic acid; FTY720, 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; FTY720-P, 2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl dihydrogen phosphate; Compound A, 1-(3-methyl-4-{[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy}benzyl)azetidine-3-carboxylic acid; Compound B, 1-[4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]benzyl]azetidine-3-carboxylic acid; RMSD, root mean square deviation; TM, trans-membrane helix; CHO, Chinese hamster ovary; FBS, Fetal Bovine Serum; PBS, Phosphate Buffered Saline; TBS, Tris Buffered Saline; PCR, Polymerase Chain Reaction; BSA, bovine serum albumin

MOL# 29223

ABSTRACT

S1P receptor agonists are novel immunosuppressive agents. The selectivity of S1P₁ against S1P₃ is strongly correlated with lymphocyte sequestration and minimum acute toxicity and bradycardia. This study describes molecular modeling, site-directed mutagenesis and affinity studies exploring the molecular basis for selectivity between S1P₁ and S1P₃ receptors. Computational models of human S1P₁ and S1P₃ receptors bound with two non-selective agonists or two S1P₁-selective agonists were developed based on the X-ray crystal structure of bovine rhodopsin. The models predict that S1P₁ Leu276 and S1P₃ Phe263 contribute to the S1P₁/S1P₃ selectivity of the two S1P₁-selective agonists. These residues were subjected to site-directed mutagenesis. The wild-type and mutant S1P receptors were expressed in Chinese hamster ovary cells and examined for their abilities to bind to and be activated by agonists in vitro. The results indicate that the mutations have minimal effects on the activities of the two non-selective agonists, while they have dramatic effects on the S1P₁-selective agonists. These studies provide a fundamental understanding of how these two receptor-selective agonists bind to the S1P₁ and S1P₃ receptors, which should aid development of more selective S1P₁ receptor agonists with immunosuppressive properties and improved safety profiles.

MOL# 29223

Introduction

Sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are important signaling molecules which activate a family of related G protein coupled receptors (GPCR) called endothelial differentiation gene (Edg) receptors (Chun et al., 2002). The receptors S1P₁ (Edg1), S1P₂ (Edg5), S1P₃ (Edg3), S1P₄ (Edg6) and S1P₅ (Edg8) bind S1P and regulate many cellular functions, including cell growth, proliferation, apoptosis, adhesion and differentiation (Pyne and Pyne, 2000; Spiegel and Milstien, 2003). A role for S1P receptors in regulating immune function was discovered when the mechanism of FTY720 (Fig. 1) was elucidated. FTY720 is in clinical trials to prevent transplant rejection (Kiuchi et al., 2000) and is metabolized rapidly in the blood to the corresponding phosphate ester, FTY720-P (Fig. 1), which is a full agonist of S1P₁, S1P₃, S1P₄ and S1P₅ (Mandala et al., 2002). FTY720 causes immunosuppression by depleting peripheral blood lymphocytes, sequestering them in secondary lymphoid organs (Chiba et al., 1998) and preventing effector lymphocyte egress from draining lymph nodes to lymph and the blood compartment (Xie et al., 2003). FTY720 also has pleiotropic cardiovascular effects. In stable renal transplant patients, it causes a dose-dependent transient bradycardia (Budde et al., 2003) and in anesthetized rats, either decreases or increases mean arterial pressure depending on the dose (Tawadrous et al., 2002).

Studies on several S1P receptor agonists with varying degrees of selectivity (Hale et al., 2004a; Li et al., 2005) indicate that S1P₁ receptor agonism is strongly correlated with lymphocyte sequestration, while S1P₃ receptor agonism is associated with acute toxicity and bradycardia in rodents (Forrest et al., 2004; Sanna et al., 2004). For example, S1P₁-selective compounds A and B (Fig. 1) effectively alter lymphocyte trafficking and have much less potential to cause bradycardia and hypertension (Hale et al., 2004a; Li et al., 2005). The toxicity and bradycardia associated with the non-selective agonists S1P and FTY720-P were also abrogated in S1P₃ ^{-/-} mice confirming that S1P₃ agonism mediates these toxicities (Forrest et al., 2004; Sanna et al., 2004). These findings led us to study how S1P₁-selective agonists bind

to S1P₁ and S1P₃.

GPCRs share a common 3D topology, consisting of seven trans-membrane helices (TMs) connected by three extracellular and three intracellular loops (Bosch et al., 2005; Fanelli and De Benedetti, 2005; van Rhee and Jacobson, 1996). S1P receptors belong to the largest subfamily A of GPCRs which includes rhodopsin for which high resolution X-ray crystal structures are available (Edwards et al., 2004; Okada et al., 2002; Okada et al., 2004; Palczewski et al., 2000; Teller et al., 2001). Although the rhodopsin molecules are in the unactivated 'dark state' in the structures, they provide attractive templates for homology modeling of family A GPCRs (Archer et al., 2003; Bosch et al., 2005; Fanelli and De Benedetti, 2005; Meng and Bourne, 2001).³ Parrill et al. proposed homology models for S1P₁ and S1P₄ receptors bound to natural ligands and agonists based on a theoretically calculated rhodopsin model (Inagaki et al., 2005; Jo et al., 2005; Parrill et al., 2000). In their models, charged Arg and Glu residues at positions 3.28 and 3.29 on TM3 of S1P₁ and S1P₄ interact with the phosphate and ammonium moieties of the natural ligand S1P, respectively.

We describe molecular models of the S1P₁ and S1P₃ receptors bound to non-selective compounds S1P, FTY720-P or S1P₁-selective compounds A or B based on the X-ray crystal structure of bovine rhodopsin (Palczewski et al., 2000). Energy-minimized conformations of agonists were docked into the proposed S1P₁ binding pocket. Two groups of residues were identified based on the nature of their interactions with the docked agonists. The first consists of Arg120(3.28) and Glu121(3.29) identified by Parrill et al. (Inagaki et al., 2005; Jo et al., 2005; Parrill et al., 2000). The second group consists of aromatic and hydrophobic residues on TM3, 5 and 6 that we propose form a hydrophobic binding pocket that interacts with the lipophilic chains of the agonists. One S1P₁ residue in this second group, Leu276(6.55), is not conserved in S1P₃ and our models predict that it contributes to the S1P₁ selectivity of compounds A and B. This S1P₁ residue and the corresponding Phe263 in S1P₃ were subjected to site-directed mutagenesis. The mutant and wild type S1P receptors were expressed in Chinese hamster ovary (CHO) cells and

MOL# 29223

examined for their abilities to bind to and be activated by agonists in vitro. Results from these experiments confirmed the predictions of our computational models and begin to provide an understanding of how compounds A and B bind S1P₁ selectively.

MOL# 29223

Materials and Methods

Sequence alignment of S1P receptors with bovine rhodopsin. The nomenclature proposed by van Rhee and Jacobson (van Rhee and Jacobson, 1996) is used to describe the amino acid residues in the S1P receptors. Each residue is represented in two parts. The first part consists of the name and sequential number of an amino acid in a given S1P receptor sequence and is followed by a parenthesis with the second part, which is the index number defined by Ballesteros and Weinstein (Ballesteros and Weinstein, 1995). In the Ballesteros-Weinstein system, each residue identifier begins with the TM number (e.g. 3 for TM3) followed by the position in the helix relative to the most highly conserved residue that is assigned number 50. For example, the charged residue pair in TM3 is represented as 3.28 and 3.29, i.e. Arg120(3.28) and Glu121(3.29) in S1P₁ and Arg114(3.28) and Glu115(3.29) in S1P₃.

Multiple sequence alignments of bovine rhodopsin, five human S1P receptors, three closely related human LPA receptors and some selected GPCR subfamily A sequences were generated with the program ClustalW (Thompson et al., 1994). After computational alignment, manual adjustments were made to eliminate gaps in the TM regions.

Three-dimensional modeling of the S1P₁ receptor. The homology model of S1P₁ was generated with the program Quanta/Modeler (Accelrys Software Inc., San Diego, CA) based on the X-ray crystal structure of bovine rhodopsin (PDB entry 1F88) (Palczewski et al., 2000). The amino-terminal 41 residues and carboxyl-terminal 51 residues of rhodopsin were excluded because of the lack of available template for these regions. The homology model was further refined using the Molecular Mechanics and Molecular Dynamics optimization to release the strain. The quality of the homology model was checked by Protein Health in Quanta (Accelrys Software Inc., San Diego, CA). The S1P₃ homology model was constructed in a similar fashion. Since S1P₁ and S1P₃ receptors share high sequence identity and similarity and the models were constructed using the same rhodopsin template, the models have very

similar topologies with a RMSD less than 1 Å for the receptor backbones. To minimize potential uncertainties introduced in modeling the flexible amino acid side chain structures, the S1P₁ homology model was used to dock agonists. The S1P₃ receptor was modeled based on the S1P₁ homology by mutating the non-conserved residues. This minimizes potential artifacts from the homology modeling while retaining the appropriate level of detail needed to select residues of interest identified through the docking studies.

Agonist docking in the S1P₁ receptor. The S enantiomer of FTY720-P is the most potent enantiomer of FTY720-P (Hale et al., 2004b) and was initially used in docking experiments because the affinities of the S1P enantiomers were unknown when these experiments were initiated. One hundred FTY720-P conformations were generated using our implementation of the distance geometry approach, which incorporates the theory and algorithm as previously described (Crippen and Havel, 1988). The conformer set was energy minimized using a distance-dependent dielectric of 2r with the MMFFs force field (Halgren, 1996). Manual docking placed the anionic phosphate and the positively charged ammonium of groups of FTY720-P close to the Arg120(3.28) and Glu121(3.29) on TM3. This docking placed the lipophilic chain of FTY720-P in a location similar to retinal in the rhodopsin-retinal complex. Since S1P and rhodopsin belong to GPCR subfamily A and the S1P receptor models were generated from and are similar to the rhodopsin crystal structure, the models place the lipophilic chains of FTY720-P in a hydrophobic pocket that is similar to that occupied by retinal between TM3, 5, 6 and 7. Ligand binding pockets lie between TM3, 5, 6 and 7 in many GPCRs and this is considered a common feature for family A GPCRs (Bondensgaard et al., 2004). Docking models of the S1P₁ receptor with FTY720-P were obtained in a stepwise fashion in order to obtain the best docking pose and to minimize potential biases introduced by initially docking FTY720-P in the S1P₁ model manually. First, the hundred conformers of FTY720-P were docked into the putative binding pocket with their lipophilic chain superimposed onto the retinal structure by SQ calculations (Miller et al., 1999). The

receptor complexes were energy optimized by MMFFs force field with the agonists fully optimized inside the binding pocket which allowed some degree of flexibility. The side chains of residues with any atom located within 5 Å of the agonists were fully minimized in conjunction with the agonists. Residues falling within 5 to 10 Å of the agonists were included in the calculations as rigid elements and the residues beyond a 10 Å cutoff from the agonist were ignored in the calculations. The total energy of the complex, the individual energies of the agonist and the receptor, and the interaction energy between the agonist and the receptor were calculated. The best docking mode was determined by selecting those poses with the most stabilizing interaction energy and minimal amount of strain on the agonist and also by visual inspection of the interactions. This receptor-agonist model was used as a second template to superpose another hundred conformers, followed by the same procedure of energy optimization of complexes. The cycles continued until the docking pose could not be improved energetically. The docking models of S1P₁ receptor with S1P, compounds A and B were derived from the final docking model of S1P₁ receptor with FTP720-P, through similar cycles of conformational searches and energy minimizations, superposition onto the template, energy optimizations of complexes and determinations of best docking poses by energy and visual check of interactions. Other docking programs, such as ICM (Molsoft LLC, San Diego, CA) were used to generate FTY720-P docking poses in the S1P₁ receptor but did not generate more energetically favorable or new models.

Synthesis. The syntheses of compound A and B have been described previously (Hale et al., 2004a; Li et al., 2005). All compounds were characterized by ¹H NMR, MS and HPLC and were judged to be >95% pure.

Cloning the human S1P₁ and S1P₃ Receptors into Expression Plasmids. An N-terminal Flag-tagged human S1P₃ receptor sequence was amplified from an expression vector provided by Kevin Lynch (University of Virginia, Charlottesville, VA) by PCR amplification using the primer set SAP470 (5'-GAATTCGCCACCATGGATTACAAGGATGACG-3') and SAP471 (5'-

GCGGCCGCTCAGTTGCAGAAGATCCCATTC-3'), which introduced a Kozak sequence, as well as *EcoRI* and *NotI* sites at the 5' and 3' termini, respectively. The accession number of the sequence of the human S1P₃ in this study is X83864 and the N-terminal Flag sequence (amino acids MDYKDDDDKSPGGS) replaces the initiator methionine codon of the human S1P₃ sequence. The PCR product was cloned into pCR4.0®-TOPO® (Invitrogen, Carlsbad, CA) and confirmed by DNA sequence analysis. The resulting plasmid, pJAC145, was digested with *EcoRI* and *NotI* and the S1P₃ fragment was subcloned into compatible sites of pBluescript-KS II+ (Stratagene, La Jolla, CA) and the mammalian expression vector pCDEF3neo (Goldman et al., 1996) which contains the human EF-1a promoter. The resulting plasmids, pJAC149 and pJAC147-9, were confirmed by DNA sequence analysis.

An N-terminal Flag-tagged human S1P₁ receptor sequence was cloned from an expression plasmid provided by Kevin Lynch (University of Virginia, Charlottesville, VA) by PCR amplification using the primer set SAP468 (5'-GGATCCGCCACCATGGACTACAAGGACGACG-3') and SAP469 (5'-GCGGCCGCCTAGGAAGAAGAGTTGACGTTTC-3'), which introduced a Kozak sequence, as well as *BamHI* and *NotI* sites at the 5' and 3' termini, respectively. The accession number of the sequence of the human S1P₁ in this study is AF233365 and the N-terminal Flag sequence (amino acids MDYKDDDDKLEL) replaces the initiator methionine codon of the human S1P₁ sequence. The PCR product was cloned into pCR4.0®-TOPO® and confirmed by DNA sequence analysis. The resulting plasmid, pGC106-26, was digested with *BamHI* and *NotI* and the S1P₁ fragment was subcloned into compatible sites of pBluescript-KS II+ and the mammalian expression vector pCDEF3neo (Goldman et al., 1996) to yield pGC109 and pGC108-C2, respectively. The sequences of the inserts in these plasmids were confirmed by DNA sequence analysis.

Site-directed mutagenesis of S1P₁ and S1P₃ receptors. The S1P₁ Leu276Phe and S1P₃ Phe263Leu mutations were created in pGC109 and pJAC149, respectively, using the Clontech Transformer™ Site-Directed Mutagenesis Kit (Clontech, Mountain View, CA) and the manufacturer's recommended

protocols. The mutagenic and selection primers and restriction enzyme used to generate the S1P₁ mutation were SAP486 (5'-phosphate-CTCTTCATCCTGTTCTGCTGGATGTG-3'), SAP505 (5'-phosphate- ATCCCGTATTGATGCCGGGCAAGAGC-3') and *Bsa*HI, respectively. The mutagenic and selection primers and restriction enzyme used to generate the S1P₃ mutation were SAP486 (5'-phosphate-CTCTTCATCCTGTTCTGCTGGATGTG-3'), SAP506 (5'-phosphate-GACTGGTGAGTATTCAACCAAGTCATT-3') and *Sca*I, respectively. The coding sequences of the S1P₁ Leu276Phe and S1P₃ Phe263Leu mutants were confirmed by DNA sequence analysis. For expression studies, the S1P₁ Leu276Phe mutant was cloned into pCDEF3neo as a *Bam*HI-*Not*I fragment. The S1P₃ Phe263Leu mutant was subcloned into the *Eco*RI-*Not*I restriction sites of vector pCDEF3neo.

Transient expression of the S1P₁ and S1P₃ receptors. For expression studies with the S1P₃ receptor, CHO cells were plated at a density of 1.6×10^6 cells per 100 mm culture dish. After 24 hours of incubation at 37 °C, cells were transfected with 2 µg of S1P₃ plasmid DNA and 100 µg of Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) in serum free Iscoves modified Dulbecco's medium (Invitrogen, Carlsbad, CA) supplemented with 1 mM sodium pyruvate and HT (0.1 mM sodium hypoxanthine and 16 µM thymidine) (Invitrogen, Carlsbad, CA) for 5 hours at 37 °C, per the manufacturer's protocol. The transfection reaction was removed from the cell monolayer and replaced with Iscoves modified Dulbecco's medium containing sodium pyruvate, HT and 10% Charcoal/ Dextran treated Fetal Bovine Serum (Hyclone, Logan, UH). Transfected cells were allowed to recover for approximately 18 hours at 37 °C. Transient transfection experiments with the S1P₁ receptor were carried out in a similar manner with 8 µg of plasmid DNA.

Production of stable cell lines expressing S1P receptors. CHO cells were transfected with plasmids encoding the S1P₁ and S1P₃ wild type or mutant receptors and clonal cell lines stably expressing the receptors were isolated in Iscoves modified Dulbecco's medium supplemented with sodium pyruvate, HT,

MOL# 29223

10% charcoal/ dextran treated fetal bovine serum after selection with G418. Stable CHO cell lines expressing the S1P₁ and S1P₃ receptors were identified in ³³P-S1P binding assays using whole cells and assay conditions described below.

Preparation of membranes from whole cells. Cell membranes were prepared from whole cells, as described previously (Mandala et al., 2002). Protein concentrations were determined using the Biorad Bradford protein assay kit II (Biorad, Hercules, CA).

Competitive ligand binding assays. Transiently transfected CHO cells expressing the S1P receptors were assayed for binding of [³³P]-sphingosine-1-phosphate (3000 Ci/mmol) using published procedures (Mandala et al., 2002), modified as described. Transfected cells were dissociated from monolayer cultures in Enzyme Free Cell Dissociation Buffer (Specialty Media, Phillipsburg, NJ), collected by centrifugation at 400 x g, washed once with PBS, and resuspended in Binding Buffer (50 mM Hepes, 5 mM MgCl₂, 1 mM CaCl₂, 0.5% BSA, and 1mM sodium vanadate) at a concentration of 2.5 x 10⁵ cells /ml. The binding reactions with whole cells were initiated by the addition of 100 µl of transfected cells (2.5 x 10⁴) to 100 ul of 0.1 nM [³³P]-S1P / cold S1P ligand in 96 well multiscreen filtration plates (Millipore, Bedford, MA). The reactions were incubated at 22 °C for one hour. After ligand binding, the reactions were washed twice with 150 µl of cold binding buffer, the assay plates was dried and 100 µl of Microscint-20 (Perkin-Elmer, Wellesley, MA) was added to each well. Plates were counted in a Packard Microplate scintillation and luminescence counter or the Wallac Trilux 1450 Microbeta Liquid Scintillation & Luminescence Counter (Perkin-Elmer Life Sciences, Wellesley, MA). Competitive ligand binding assays with membranes prepared from stably transfected CHO cells and 0.1 nM [³³P]-S1P/cold S1P ligand were performed as described (Mandala et al., 2002). Assays of the S1P₃ receptors were performed with 0.25 µg of membrane protein. Western hybridization (see Figure 6 in Results) and radioligand binding experiments titrating membrane protein concentration (data not shown) indicated that

MOL# 29223

the S1P₁ Leu276Phe receptor was expressed at a higher density than the wild type receptor in the stable CHO cell lines. Competition binding assays of the S1P₁ wild type and S1P₁ Leu276Phe receptors were performed with 0.57 and 0.285 µg, respectively. Binding experiments were performed in triplicate in three separate experiments. Data were analyzed by nonlinear regression using a one-site competition model in the program Prism (GraphPad Software, San Diego, CA) to determine Log IC₅₀. The Log IC₅₀ values from each experiment were analyzed in an unpaired Student's t test.

S1P Saturation Binding Assays. The K_d and B_{max} values of mutant and wild type receptors in membrane fractions from the stable CHO cell lines expressing the S1P₁ or S1P₃ receptors were determined in saturation binding assays with [³³P]-S1P (3000 Ci/mmol) in two experiments performed in triplicate. A cocktail of cold S1P and [³³P]-S1P ligand was titrated in triplicate in a 6 point titration, ranging from 3 nM S1P to 0.025 nM in binding buffer. In a prewet 96 well multiscreen filtration plates (Millipore, Medford, MA), 100 µl of each ligand dilution was added to each reaction well. Two µl of 50 µM cold S1P was added to a parallel set of reactions to determine non-specific binding. Reactions were initiated by the addition of membrane fractions, incubated at 22° C for one hour and washed twice with 150 µl of cold binding buffer. After drying assay plates at 40 ° C for one hour, 100 µl of Microscint-20 (Perkin Elmer Life Sciences, Wellesley, MA) was added to each well and the plates were counted in a Wallac Trilux 1450 Microbeta Liquid Scintillation and Luminescence Counter (Perkin Elmer Life Sciences, Wellesley, MA). Data were analyzed by nonlinear regression and fit to a one site binding model using the program Prism to determine the K_d and B_{max} values (GraphPad Software, San Diego, CA).

Measurements of ³⁵S-GTPγS binding. ³⁵S-GTPγS (1250 Ci/mmol) binding was assayed in membranes (3 µg) prepared from CHO cell lines as described previously (Mandala et al., 2002). The reactions were incubated at 22 °C for one hour and washed six times with distilled water using a Packard

filtermate harvester. After drying the reaction plates at 50 °C, 50 µl of ScintiSafe Plus 50% (Fisher, Pittsburgh, PA) was added to each well and the plates were counted in a Microplate scintillation and luminescence counter or a Wallac Trilux 1450 Microbeta Liquid Scintillation and Luminescence Counter. ³⁵S-GTPγS binding assays were performed in triplicate in three separate experiments. Data were analyzed by nonlinear regression and fit to a sigmoidal dose response curve using the program Prism (GraphPad Software, San Diego, CA) to determine the Log EC₅₀ values. The Log EC₅₀ values of individual compounds for the wild type and mutant receptors were analyzed in an unpaired Student's t test. The efficacies (*E*_{max}) of the agonists tested to stimulate ³⁵S-GTPγS binding were calculated as the percentage of the maximal increase obtained using 5 µM S1P on the wild type S1P₁ or S1P₃ receptors.

S1P₁ and S1P₃ antisera. The C-terminal S1P₁ rabbit antiserum MS1766 has been described previously (Forrest et al., 2004). A peptide in the N-terminus of human S1P₃ (REHYQYVGKLAGRLKEASE) was synthesized (SynPep Corp, Dublin, CA), conjugated to KLH, and used to immunize rabbits (Covance Research Products, Denver, PA). Specific IgG fractions were affinity purified using the immunizing peptide and tested by western hybridization against a panel of human, mouse and rat S1P receptors. The S1P₃ antiserum MS2284 was specific for the human S1P₃ receptor.

Confocal Microscopy Studies of S1P₁ and S1P₃ Receptor Expression. Stable CHO clones expressing the receptors were plated in four chambers of the Lab-Tek II Chamber #1.5 German Coverglass System at a density of 40,000 cells per chamber, in Iscoves modified Dulbecco's medium with sodium pyruvate, HT and 10% charcoal/ dextran treated fetal bovine serum, and 25 mM Hepes buffer, pH 7.5. Cells were allowed to adhere for 24 hours at 37 °C. Growth medium was removed and cells were washed / equilibrated with FACS buffer (1x PBS containing 2.5% charcoal/ dextran treated fetal bovine serum, 25 mM Hepes, and 0.05% NaN₃). To detect S1P₃, adherent cells were blocked with goat IgG blocking antibody (MP Biomedicals, Irvine, CA) at 100 µg / ml in FACS buffer. After 10 minutes of incubation at

MOL# 29223

22 °C, cells were incubated with receptor-specific antisera, including a rabbit S1P₁ antiserum (MS1766) or a rabbit S1P₃ antiserum (MS2284) at 100 µg / ml in a 200 µl reaction volume. A normal rabbit anti-IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA) served as the isotype control. In addition, the fourth chamber of cells did not receive antibody and served as the non-specific fluorescence control. Cells were incubated for 30 minutes at 22 °C, followed by 2 washes with FACS buffer. Cells were then incubated with a secondary goat anti-rabbit IgG FITC-labeled antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 25 µg / ml for 30 minutes at 22 °C. Cells were washed two times with FACS buffer, fixed with BD Cytofix/Cytoperm™ solution (BD Biosciences Pharmingen, San Diego, CA) and washed with BD Perm/Wash™ solution (BD Biosciences Pharmingen, San Diego, CA) that was diluted in FACS buffer according to the manufacturer's protocol. The stained cells were then washed with FACS buffer, washed twice with PBS, overlaid with PBS containing 5 nM DRAQ5™ (Biostatus Limited, Leicestershire, UK) and viewed by confocal microscopy.

To detect S1P₁, adherent cells were washed with FACS buffer, and fixed / permeablized in BD Cytofix/Cytoperm™ solution according to the manufacturer's protocol. Cells were washed and maintained in BD Perm/Wash™ buffer. Cells were then hybridized with MS1766 or MS2284 and viewed by confocal microscopy following the same procedure described for detection of S1P₃.

Western Hybridization Analysis of S1P₁ and S1P₃ Receptor Expression. Membrane fractions from transiently transfected populations of CHO cells expressing the S1P receptors were separated on 12% Precise Protein Gels (Pierce, Rockford, IL). Biorad Precision Plus Protein Standards (Biorad, Hercules, CA) were electrophoresed in adjacent wells for size determinations. Proteins were transferred to a 0.45µm Immobilon-P PVDF membrane (Millipore, Bedford MA) for 2 hours at 75 V. The membranes were washed with 1x TBS + 0.05% Tween-20 (which was also included in all subsequent wash steps) and blocked with Starting Block (TBS) blocking buffer (Pierce, Rockford, IL) containing 0.05% Tween-20.

MOL# 29223

Hybridization of rabbit S1P₁ antiserum (MS1766) (1:1000 dilution) or rabbit S1P₃ antiserum (MS2844) (1:3000) was performed in Starting Block buffer at 4 °C for 16 hours. After three 5 minute washes, the membranes were incubated with a stabilized goat anti-rabbit IgG-HRP conjugated antibody (Pierce, Rockford, IL) at a 1:3000 dilution (S1P₁) or 1:20,000 dilution (S1P₃) for one hour at 22 °C. Hybridization was detected with the Pierce ECL-femto kit following the manufacturer's protocol, using CL-X Posure film (Pierce, Rockford, IL).

MOL# 29223

Results

Homology modeling of the S1P₁ and S1P₃ receptors. To model the structures of the S1P receptors, we aligned their primary amino acid sequences with other members of the GPCR A subfamily in order to optimize the sequence alignment. Bovine rhodopsin was used as the structural template for the homology model. The alignment of TM3, 4, 5, 6 and 7 of S1P receptors with bovine rhodopsin is illustrated in Fig. 2. The most conserved residues in the family A GPCRs are conserved in six of the seven TM domains in S1P receptors, except TM5. The most highly conserved Pro (5.50) in TM5 of the family A GPCRs is replaced by hydrophobic residues in the S1P receptors, i.e. Leu in S1P₁, Ile in S1P₂, S1P₃ and S1P₅, and Val in S1P₄ (Fig. 2). However, another highly conserved residue, Tyr (5.58) (Bosch et al., 2005), is present in all five S1P receptors. In many of the family A GPCRs, a disulfide bond exists between TM3 and the second extracellular loop between TM4 and TM5 (Bosch et al., 2005). For example, in bovine rhodopsin, the disulfide bond is formed between residue Cys110(3.25) and Cys187 (Palczewski et al., 2000). This disulfide bond does not exist in the S1P receptors which contain a Trp in TM3 in place of Cys at position 3.25.

The S1P₁ and S1P₃ receptors share the highest degree of amino acid sequence relatedness in the S1P receptor family, with approximately 50% of the residues identical, another 20% of the residues strongly similar and more than 10% of the residues weakly similar. Since the S1P₁ and S1P₃ receptors are highly conserved, the S1P₁ homology model was used for docking of agonists. The S1P₁ homology model displays a three dimensional structure similar to bovine rhodopsin, with a seven TM helical bundle and a short cytoplasmic helix (Fig. 3). The S1P₃ receptor was modeled based on the S1P₁ homology model, focusing on the non-conserved residues.

Structure of the agonist binding pocket of the S1P₁ and S1P₃ receptors. The compounds used in this

study included the natural ligand S1P, FTY720-P which is a phosphate ester of FTY720, and compounds A and B which are S1P₁-selective agonists (Fig. 1). These compounds share common structural characteristics including charged head groups and long lipophilic side chains. The S-enantiomeric phosphate ester of FTY720-P was used to generate models of agonist-bound S1P₁ receptor complexes for several reasons. It is a more potent agonist of the human S1P₁ receptor than the R-enantiomer (Hale et al., 2004b) and is an agonist of S1P₃, S1P₄ and S1P₅. The R-enantiomer is a full agonist of S1P₁ and S1P₄ but its potency at these receptors is lower and it is an antagonist of S1P₃ and S1P₅. At the time these experiments were initiated, the agonist/antagonist activities and affinities of the enantiomeric phosphate esters of S1P against the S1P receptor family were also unknown.

In the agonist docking models, S1P, FTY720-P and the S1P₁-selective compounds A and B, bind to a common pocket that contains conserved receptor-agonist interactions. The preferred docking mode for agonists in these models is depicted in Fig. 3, in which FTY720-P is illustrated. The agonists are bound in the upper half of the TM helical bundle, towards the extracellular surface. The agonists have an extended conformation in a narrow binding pocket and are surrounded by residues mainly from TM3, 5 and 6, and a few residues from TM4 and 7. Amino acid residues with any atom located within 4Å of ligands in the docking models are indicated with asterisks in Fig. 2 and are highlighted in green or yellow (Leu276(6.55)) in Figure 3.

Further examination of receptor residues within 4Å of the agonists in the binding pocket identified two groups of interactions (Fig. 4). The first group consists of the charged residues on TM3, Arg120(3.28) and Glu121(3.29), identified by Parrill et al. (Inagaki et al., 2005; Jo et al., 2005; Parrill et al., 2000). These receptor residues interact with the charged head groups of agonists in our models. For example, the distance between the anionic phosphate group of FTY720-P and the positively charged side chain of Arg120(3.28) of S1P₁ is approximately 2.5 Å; similarly, the ammonium of FTY720-P is within 2.6 Å of the negatively charged side chain of Glu121(3.29) (Fig. 4B). The second group of interactions consists of

nine aromatic and hydrophobic amino acids, adjacent to the lipophilic side chains of the agonists. These residues include Phe125(3.33), Leu128(3.36), Phe205(5.42), Phe210(5.47), Phe265(6.44), Trp269(6.48), Leu272(6.51), Phe273(6.52) and Leu276(6.55). Eight of these residues are conserved between S1P₁ and S1P₃ receptors. The ninth residue, Leu276(6.55) in S1P₁ is replaced by Phe263(6.55) in S1P₃ (Figure 2). In the S1P₁-agonist docking models, Leu276(6.55) forms van der Waals interactions with the phenyl ring and azetidine of compounds A and B (Fig. 4C and 4D). In the S1P₃ model, the bulkier Phe263 residue reduces the size of the binding pocket and sterically hinders binding of compounds A and B to the receptor. These results suggested that the Leu276/Phe263 residues contribute to the S1P₁/ S1P₃ selectivity of compounds A and B.

S1P₁ and S1P₃ receptor binding assays. We developed a competitive receptor binding assay using CHO cells transiently transfected with the S1P₁ and S1P₃ receptors in order to rapidly assay agonist binding to the receptor mutants. In this assay, S1P inhibited the binding of [³³P]-S1P to the S1P₁ and S1P₃ receptors with high affinity (Fig. 5A and B). When assayed in binding assays using transiently transfected receptors, compound A bound S1P₁ with high affinity and exhibited selectivity for S1P₁ over S1P₃ (Fig. 5).

To investigate the role of the S1P₁ Leu276 and S1P₃ Phe263 residues in the selectivity of compound A, we constructed S1P₁ Leu276Phe and S1P₃ Phe263Leu mutant receptors by site-directed mutagenesis and assayed the abilities of the receptors to bind S1P and compound A in transiently transfected cells. The S1P₁ Leu276Phe and S1P₃ Phe263Leu mutants bound S1P with high affinities similar to those of the wild type receptors (Fig. 5). The S1P₁-selective compound A bound to the S1P₁ Leu276Phe mutant receptor with lower affinity compared to the wild type S1P₁ receptor. Conversely, the S1P₃ Phe263Leu mutant receptor bound to compound A with higher affinity compared to the wild type S1P₃ receptor.

Wild-type and mutant S1P receptors are expressed on the cell surface of stable cell lines. Stable

MOL# 29223

CHO cell lines expressing the wild type and mutant S1P₁ and S1P₃ receptors were generated to expand the characterization of the mutant S1P₁ Leu276Phe and S1P₃ Phe263Leu receptors. Expression patterns of the wild type and mutant receptors in the stable cells lines were characterized by western hybridization and confocal microscopy. Murine S1P₁ is N-glycosylated in the ectodomain on an asparagine residue in CHO cell lines over expressing the receptor and this residue is conserved in S1P₂, S1P₄ and S1P₅ (Kohno et al., 2002). The amino-terminal ectodomains of murine S1P₁ and S1P₃ are also truncated in over expressing CHO cells (Kohno and Igarashi, 2003). We have observed similar findings with the stable cell lines expressing the human wild type and mutant S1P₁ and S1P₃ receptors. The predicted size of the flag-tagged human S1P₁ receptors in these experiments is 44.3 kDa. The S1P₁-specific antiserum recognize proteins of approximately 54.3, 49.2 and 44.5 kDa in membranes prepared from the cell lines expressing the wild type receptor and proteins of approximately 54.3 and 49.2 kDa in membranes prepared from the cell line expressing the Leu276Phe S1P₁ receptor (Figure 6A). Results from these experiments indicate that the stable cell line expressing the S1P₁ Leu276Phe receptor expressed approximately 5-fold more receptor than the cell line expressing the wild type receptor. The sizes of the human S1P₁ wild type and Leu276Phe receptors expressed in CHO cells indicate that these receptors are glycosylated. We have also observed that the wild type and mutant S1P₁ receptors do not cross-react with an antibody that recognizes the Flag tag (data not shown) indicating that human S1P₁ receptors are also truncated at the N-terminus. Proteins of approximately 47.7 kDa were detected in membranes from the cell lines expressing the S1P₃ wild type and Phe263Leu receptors (Figure 6B). The predicted sizes of the flag-tagged S1P₃ receptors are 43.8 kDa suggesting the receptors are migrating anomalously or are post-translationally modified. The wild type and mutant S1P₃ receptors were also not recognized by the Flag antibody (data not shown) indicating that the human S1P₃ receptors are also truncated at the N-terminus.

We also examined localization of the wild type and mutant receptors by confocal microscopy (Fig. 7). The S1P₁ antiserum recognized S1P₁ wild type or Leu276Phe mutant receptors at the cell surface indicating that the Leu276Phe mutation did not alter trafficking of the receptor in cells. Similar results

were obtained when localization of the S1P₃ wild type and Phe263Leu mutant receptors were examined with the S1P₃ antiserum.

The S1P₁ Leu276Phe and S1P₃ Phe263Leu mutations alter the binding affinities and agonist activities of compounds A and B. The K_d and B_{max} of the wild type and mutant receptors in membranes prepared from the stable cell lines were also determined in saturation binding assays with [³³P]-S1P (Table 1). The K_d values for the S1P₁ wild type and Leu276Phe receptors were 0.39 and 0.29 nM, respectively. In these experiments, the B_{max} values of the wild type and mutant receptors were 9.26 and 13.89 fmoles/μg, respectively, indicating that the receptor density of the mutant receptor is higher than that of wild type S1P₁. These results indicate that the Leu276Phe mutation in S1P₁ does not alter the conformation of the receptor dramatically resulting in a large change in affinity for the ligand. Similar results were observed in saturation binding assays with the S1P₃ wild type and Phe263Leu mutant receptors. The K_d values for the S1P₃ wild type and Phe263Leu receptors were 0.23 and 0.22 nM, respectively. The B_{max} values of the stable cell line expressing the wild type and mutant S1P₃ receptors were 14.24 and 15.98 fmoles/μg, respectively.

The affinities of S1P, FTY720-P, compound A and compound B for the wild type and mutant receptors were assayed in competitive binding assays with membrane fractions prepared from stable clones expressing the wild type and mutant receptors. Log IC₅₀ values are indicated in Table 2. Unlabeled S1P competed [³³P]-S1P from the wild type and mutant S1P₁ receptors with similar high affinities (Log IC₅₀ values of -9.20 and -9.29 M, respectively). FTY720-P also competed [³³P]-S1P from the wild type and mutant S1P₁ receptors with Log IC₅₀s of - 8.96 and -8.88 M, respectively. The affinities of S1P and FTY720-P for the wild type and mutant S1P₃ receptors were also comparable. S1P competed [³³P]-S1P from the wild and mutant S1P₃ receptors with Log IC₅₀s of -9.35 and -9.29 M,

respectively, while FTY720-P competed [^{33}P]-S1P from these receptors with Log IC_{50} s of -8.57 and -8.41 M, respectively.

To examine the contribution of S1P₁ Leu276 and S1P₃ Phe263 residues to S1P₁-selective compounds A and B, we determined the Log IC_{50} s of these compounds for the wild type and mutant S1P₁ and S1P₃ receptors (Table 2). Compound A bound to the wild type S1P₁ receptor with approximately 13 fold higher affinity than to the S1P₁ Leu276Phe receptor. The Log IC_{50} of compound A on the mutant receptor was -7.37 M. The S1P₁-selective agonist compound B bound to wild type S1P₁ receptor with approximately 40 fold higher affinity than to the Leu276Phe mutant with a Log IC_{50} of -7.33 M. In contrast, the S1P₁-selective compounds bound with approximately 10 and 151-fold higher affinities to the mutant S1P₃ Phe263Leu receptor when compared to the wild type receptor. The Log IC_{50} s of compounds A and B for the S1P₃ Phe263Leu mutant were -6.71 and -7.56 M, respectively.

The potencies and efficacies of S1P, FTY720-P and compounds A and B for the wild type and mutant receptors were also evaluated in [^{35}S]-GTP γ S binding assays (Figure 8 and Table 3). The basal activities (mean $\pm$ S.E.) of the S1P₁ wild type and mutant receptors were 1102 ± 137 and 862 ± 51 fmoles/mg, respectively and S1P activated the receptors with similar affinities (Log EC_{50} of -7.48 and -7.58 M, respectively). In our in vitro experiments measuring [^{35}S]-GTP γ S binding, the potency of S1P as an agonist of the S1P wild type and mutant receptors is approximately 50 fold lower than the affinity of S1P for these receptors in competition binding assays. This decrease in potency is due a phosphatase activity in CHO membrane preparations over expressing the S1P₁ receptor (J. Milligan, G.J. Shei and S. Mandala, data not shown). This activity hydrolyzes S1P resulting in a loss of potency of the natural agonist in the [^{35}S]-GTP γ S binding assay. S1P also induced a significant agonist response by the mutant receptor (E_{max} 115%). The basal activities (mean $\pm$ S.E.) of the S1P₃ wild type and mutant receptors were 1555 ± 73 and 2065 ± 50 fmoles/mg, respectively. The Log EC_{50} values of S1P for the wild type and mutant

MOL# 29223

S1P₃ receptors were -8.45 and -8.64 M, respectively, and S1P activated the S1P₃ mutant receptor efficiently (*E*_{max} 82%). The S1P₃ Phe263Leu mutation had minimal effects on the basal activity of the receptor (Figure 8). Although FTY720-P was a potent and efficacious agonist of the mutant S1P₁ Leu276Phe receptor (Log EC₅₀ = -8.76 M, *E*_{max} = 109%), the compound was a 6-fold more potent agonist of the wild type receptor (Log EC₅₀ = -9.54 M, *E*_{max} = 95%). FTY720-P was also a potent agonist of the wild type and mutant S1P₃ receptors with Log EC₅₀ values of -8.87 and -9.07 M, respectively. This synthetic agonist also activated the wild type and mutant S1P₃ receptors effectively with *E*_{max} values of 106 and 93%, respectively.

The S1P₁ Leu276Phe and S1P₃ Phe263Leu mutations had significant affects on the agonist potencies of compounds A and B (Figure 8 and Table 3). The S1P₁-selective compounds A and B were potent and efficacious agonists of the wild type S1P₁ receptor. The Log EC₅₀ values of the compounds were -8.81 and -9.61 M, respectively. The potencies of S1P₁-selective compounds A and B for the S1P₁ Leu276Phe mutant were lower when compared to the wild type receptor with Log EC₅₀s of -6.90 and -6.66 M, respectively. Despite a decrease in potency, compounds A and B activated the mutant S1P₁ receptor effectively with *E*_{max} values of 103 and 116%, respectively. In contrast, compounds A and B were more potent agonists of the S1P₃ Phe263Leu mutant when compared to the wild type S1P₃ receptor. The Log EC₅₀ values of the compounds against the wild type S1P₃ receptor were -6.34 and -5.85 M, respectively. Both S1P₁-selective agonists were more potent agonists of the S1P₃ Phe263Leu receptor with Log EC₅₀s of -7.97 and -8.98 M, respectively. Both compounds A and B were also effective agonists of the wild type and mutant S1P₃ receptors with *E*_{max} values ranging from 80-128%.

MOL# 29223

Discussion

The S1P receptors share high homology in their primary sequences and, as expected, the agonist binding pockets of the S1P₁ and S1P₃ receptors predicted by our modeling studies overlap and share conserved residues that interact with agonists. This is consistent with findings that many S1P receptor agonists do not exhibit significant receptor subtype selectivity. The potential clinical advantage of S1P receptor agonists lacking S1P₃ activity has prompted development of S1P₁/S1P₃ selective agonists and led us to study receptor-agonist interactions and receptor structural features that contribute to S1P₁/S1P₃ selectivity. Our modeling studies and mutagenesis experiments indicate that Leu276(6.55) in S1P₁ and Phe263(6.55) in S1P₃ are critical residues that contribute to the S1P₁-selectivity of compounds A and B.

In our docking models, the agonists bind S1P₁ in a narrow cavity located in the upper half of the seven TM helical bundle. The binding pocket consists of residues located on TM3, 5, 6 and 7. Similar pockets have been identified in many GPCRs by mutagenesis studies and are regarded as a common feature for family A GPCRs (Bondensgaard et al., 2004). Interactions between charged residues on TM3 and charged agonists or antagonists are found in many GPCRs (Feighner et al., 1998; Shin et al., 2002). The importance of S1P interactions with Arg120(3.28) and Glu121(3.29) in the S1P₁ receptor were revealed by mutagenesis studies directed by a model generated from a theoretically-calculated structure of bovine rhodopsin (Parrill et al., 2000). Our model, which is based on the X-ray structure of bovine rhodopsin in the dark state, and mutagenesis studies on the human S1P₁ and S1P₃ receptors confirm these findings (data not shown). The charged residues at the top of the binding pocket interact with the counter-ions in the charged head groups of the agonists. These conserved residues (Fig. 2) play important roles in recognizing charged agonists in all S1P receptors. Arg120(3.28) is also conserved in LPA receptors but Glu121(3.29) is substituted with a Gln in LPA receptors. These LPA receptor residues are key determinants of their ligand specificity (Wang et al., 2001).

MOL# 29223

The hydrophobic domain of the proposed binding pocket of the S1P₁ receptor is adjacent to the lipophilic side chain of the agonists used in this study. Based on our docking models, a group of aromatic and hydrophobic residues line the wall of the binding pocket. These residues are located deep in the pocket and provide important interactions with the lipophilic side chain of the agonists. Some of these residues, Phe125(3.33), Phe273(6.52) and Trp269(6.48), have also been proposed to interact with S1P₁ agonist SEW2871 (Jo et al., 2005). S1P₁ residues Phe210(5.47), Phe265(6.44) and Trp269(6.48) are among a group of highly conserved residues in many family A GPCRs (Bondensgaard et al., 2004). Previous mutagenesis studies illustrate the importance of aromatic residues in TM3 and 6 in the binding and activation of GPCRs by agonists (Holst et al., 2004; Renzetti et al., 1999; Spalding et al., 1998).

Our examination of the predicted agonist binding pockets of S1P₁ and S1P₃ identified a non-conserved Leu at position 6.55 in S1P₁. Four of five S1P receptors also contain a Leu at this position while S1P₃ contains a Phe residue at the equivalent position. In our models, Leu276 in S1P₁ and Phe263 in S1P₃ affect the sizes of the binding pockets. The volume of the Phe aromatic side chain is about 25% larger than that of the aliphatic Leu side chain, making the S1P₃ binding pocket more crowded than the S1P₁ pocket. In the S1P₁ docking models, Leu276(6.55) is close to the phenyl ring and azetidine of S1P₁-selective compounds A and B (Fig. 4C and 4D). The rigidity of these regions of compounds A and B makes it difficult for them to assume conformations that fit in the smaller binding pocket of the S1P₃ receptor, explaining their S1P₁ selectivity. When Leu276(6.55) is replaced with a Phe in the S1P₁ model, the binding pocket is smaller because of the bulkier size of the Phe side chain.

To test this model, we constructed S1P₁ and S1P₃ receptor mutants in which the Leu276 and Phe263 residues were exchanged and examined their expression and activity in western hybridization, confocal microscopy and radioligand binding experiments. These experiments indicate that the S1P₃ wild and mutant receptors are over expressed on the surface of the stable CHO cell lines at similar densities and that both receptors bind S1P with high affinity. The K_d values of S1P for both receptors are

MOL# 29223

approximately 0.2 nM. S1P binds the wild type and mutant S1P₁ receptors with high affinity, with K_d values of 0.39 and 0.29 nM, respectively. The S1P₁ receptors are over expressed on the surface of the stable CHO cells. Results from the western hybridization experiments indicate that the mutant receptor is expressed at approximately 5-fold higher density than the wild type receptor while our ligand binding studies with [³³P]-S1P indicate that the mutant receptor density is approximately 2-fold higher than the wild type receptor. These results indicate that a fraction of the S1P₁ Leu276Phe receptors may be in a conformation that does not bind S1P with high affinity.

The competitive ligand binding and agonist functional studies comparing the S1P₁ and S1P₃ wild type and mutant receptors confirm the predictions of the molecular models we developed for these receptors. The S1P₁ Leu276Phe mutant has a significantly reduced affinity for S1P₁-selective compounds A and B, and both of these agonists activate the S1P₁ mutant with much poorer potencies. On the other hand, substituting Phe263(6.55) of the S1P₃ receptor with Leu in the S1P₃ receptor enlarges the binding pocket of this mutant S1P₃ receptor, leading to an increase in the binding affinity and agonist potency of compounds A and B. This prediction was also verified experimentally with the S1P₃ Phe263Leu mutant. Additionally, our conformational analyses of compounds A and B indicate that compound B is more rigid than compound A (data not shown), making it more difficult to assume a conformation that fits the binding pocket of the S1P₃ receptor and more susceptible to changes at Leu276 and Phe263 of the S1P₁ and S1P₃ receptors, respectively. Our in vitro analyses of the interactions of compounds A and B with the wild type and mutant receptors demonstrate that the mutations have more dramatic effects on the binding affinity and agonist potency of compound B.

In contrast to S1P₁-selective compounds A and B, S1P contains a long, highly flexible alkyl side chain that easily adopts a conformation to bind to S1P₁ and S1P₃. It binds to both receptors with comparable affinities and is not sensitive to the Leu and Phe substitution mutations we constructed in S1P₁ and S1P₃. FTY720-P is also a high-affinity agonist of S1P₁ and S1P₃ with a slightly higher agonist potency against

MOL# 29223

S1P₁. Our models predict that FTY720-P has a higher potency for S1P₁ because it contains a phenyl ring and prefers a larger binding pocket. The phenyl ring of FTY720-P is four bonds away from the positively charged ammonium group and seven bonds away from the negatively charged phosphate group. The longer linker between the charged head group and the phenyl ring of FTY720-P is more flexible than the azetidine moiety in S1P₁-selective compounds A and B. The models suggest that this flexibility is the reason FTY720-P is affected less by changes of the Leu276 and Phe263 residues in the binding pockets of S1P₁ and S1P₃. Although significant changes in FTY720-P binding affinity for the mutant or wild type receptors were not observed in competition binding assays, the S1P₁ Leu276Phe mutation did confer a statistically significant change in agonist potency measured in vitro. FTY720-P activates the wild type S1P₁ receptor 6-fold more potently than the S1P₁ Leu276Phe receptor, which contains a significantly smaller binding pocket.

These models predict that residues Leu276(6.55) and Phe263(6.55) are important contributors to S1P₁ and S1P₃ specificities of compounds A and B. However, the changes in agonist binding affinities and potencies observed with these mutations do not fully interconvert the pharmacological profiles of either agonist, indicating that other residues within the binding pocket also contribute to the specificities of these subtype-selective agonists. There are seven non-conserved residues in S1P₁ and S1P₃ within 4 Å of the predicted agonist binding pocket (Val3.40Thr, Val5.46Ile, Leu5.50Ile, Leu6.41Val, Ala6.49Ser, Leu6.55Phe and Leu7.39Ile). Except for Leu276Phe, these residues are predicted to have smaller effects on the specificities of compounds A and B based on their positions and orientations. Combining the S1P₁ Leu276Phe or S1P₃ Phe263Leu mutations with amino acid substitutions in the other six non-conserved residues in S1P₁ and S1P₃ in the predicted agonist binding pocket may interconvert the pharmacological profiles of these agonists completely. Models of GPCR-agonist complexes based on X-ray crystal structures of rhodopsin in the unactivated 'dark state' also have an inherent bias that might mask important receptor interactions with agonists.³

MOL# 29223

Our integrated molecular modeling and site-directed mutagenesis studies of the S1P₁ and S1P₃ receptors bound to non-selective and S1P₁-selective agonists provide additional insights into the nature of different S1P receptor-agonist interactions and identify an important pair of residues in S1P₁ and S1P₃ that contribute significantly to receptor subtype selectivity of compounds A, B and FTY720-P. These findings provide a molecular basis for understanding S1P₁/S1P₃ subtype-selectivity of these S1P receptor agonists, which should aid development of more selective S1P₁ receptor agonists with immunosuppressive properties and improved safety profiles.

Acknowledgements

The authors are grateful to Hugh Rosen for encouragement and support in the early stages of this work. We thank James Milligan for synthesis of the radioligand used in the saturation binding assays, members of the Mandala laboratory for assay protocols and help in screening and characterizing antiserum MS2284, and Kevin Lynch for providing the expression plasmids encoding the human S1P₁ and S1P₃ receptors. We are also grateful to Michele McColgan and Sharon O'Brien for preparing the Figures and Elizabeth Quackenbush for comments on the manuscript.

MOL# 29223

References

- Archer E, Maigret B, Escrieut C, Pradayrol L and Fourmy D (2003) Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? *Trends Pharmacol Sci* **24**:36-40.
- Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. *Methods Neurosci* **25**:366-428.
- Bondensgaard K, Ankersen M, Thogersen H, Hansen BS, Wulff BS and Bywater RP (2004) Recognition of privileged structures by G-protein coupled receptors. *J Med Chem* **47**:888-899.
- Bosch L, Iarriccio L and Garriga P (2005) New prospects for drug discovery from structural studies of rhodopsin. *Curr Pharm Des* **11**:2243-2256.
- Budde K, L. Schmouder R, Nashan B, Brunkhorst R, W. Lucker P, Mayer T, Brookman L, Nedelman J, Skerjanec A, Bohler T and Neumayer H-H (2003) Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients. *American Journal of Transplantation* **3**:846-854.
- Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M and Hoshino Y (1998) FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. I. FTY720 Selectively Decreases the Number of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing. *J Immunol* **160**:5037-5044.
- Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, Pyne S and Tigyi G (2002) International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. *Pharmacol Rev* **54**:265-269.
- Crippen GM and Havel TF (1988) *Distance Geometry and Molecular Conformation*. Wiley, New York.
- Edwards PC, Li J, Burghammer M, McDowell JH, Villa C, Hargrave PA and Schertler GF (2004) Crystals of native and modified bovine rhodopsins and their heavy atom derivatives. *J Mol Biol* **343**:1439-1450.
- Fanelli F and De Benedetti PG (2005) Computational modeling approaches to structure-function analysis of G protein-coupled receptors. *Chem Rev* **105**:3297-3351.
- Feighner SD, Howard AD, Prendergast K, Palyha OC, Hreniuk DL, Nargund R, Underwood D, Tata JR, Dean DC, Tan CP, McKee KK, Woods JW, Patchett AA, Smith RG and Van der Ploeg LH (1998) Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. *Mol Endocrinol* **12**:137-145.
- Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer, II, Tian M, West S, White V, Xie J, Proia RL and Mandala S (2004) Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. *J Pharmacol Exp Ther* **309**:758-768.
- Goldman LA, Cutrone EC, Kotenko SV, Krause CD and Langer JA (1996) Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. *Biotechniques* **21**:1013-1015.

MOL# 29223

- Hale JJ, Lynch CL, Neway W, Mills SG, Hajdu R, Keohane CA, Rosenbach MJ, Milligan JA, Shei GJ, Parent SA, Chrebet G, Bergstrom J, Card D, Ferrer M, Hodder P, Strulovici B, Rosen H and Mandala S (2004a) A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. *J Med Chem* **47**:6662-6665.
- Hale JJ, Yan L, Neway WE, Hajdu R, Bergstrom JD, Milligan JA, Shei GJ, Chrebet GL, Thornton RA, Card D, Rosenbach M, HughRosen and Mandala S (2004b) Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720. *Bioorg Med Chem* **12**:4803-4807.
- Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. *Journal of Computational Chemistry* **17**:490-519.
- Holst B, Holliday ND, Bach A, Elling CE, Cox HM and Schwartz TW (2004) Common structural basis for constitutive activity of the ghrelin receptor family. *J Biol Chem* **279**:53806-53817.
- Inagaki Y, Pham TT, Fujiwara Y, Kohno T, Osborne DA, Igarashi Y, Tigyi G and Parrill AL (2005) Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. *Biochem J* **389**:187-195.
- Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, Hla T, Parrill AL and Rosen H (2005) S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. *Chem Biol* **12**:703-715.
- Kiuchi M, Adachi K, Kohara T, Minoguchi M, Hanano T, Aoki Y, Mishina T, Arita M, Nakao N, Ohtsuki M, Hoshino Y, Teshima K, Chiba K, Sasaki S and Fujita T (2000) Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. *J Med Chem* **43**:2946-2961.
- Kohno T and Igarashi Y (2003) Truncation of the N-Terminal Ectodomain Has Implications in the N-Glycosylation and Transport to the Cell Surface of Edg-1/S1P1 Receptor. *J Biochem (Tokyo)* **134**:667-673.
- Kohno T, WADA A and IGARASHI Y (2002) N-Glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization. *FASEB J.* **16**:983-992.
- Li Z, Chen W, Hale JJ, Lynch CL, Mills SG, Hajdu R, Keohane CA, Rosenbach MJ, Milligan JA, Shei GJ, Chrebet G, Parent SA, Bergstrom J, Card D, Forrest M, Quackenbush EJ, Wickham LA, Vargas H, Evans RM, Rosen H and Mandala S (2005) Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3. *J Med Chem* **48**:6169-6173.
- Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W and Rosen H (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. *Science* **296**:346-349.
- Meng EC and Bourne HR (2001) Receptor activation: what does the rhodopsin structure tell us? *Trends Pharmacol Sci* **22**:587-593.
- Miller MD, Sheridan RP and Kearsley SK (1999) SQ: a program for rapidly producing pharmacophorically relevant molecular superpositions. *J Med Chem* **42**:1505-1514.
- Nakamichi H and Okada T (2006a) Crystallographic analysis of primary visual photochemistry. *Angew Chem Int Ed Engl* **45**:4270-4273.

- Nakamichi H and Okada T (2006b) Local peptide movement in the photoreaction intermediate of rhodopsin. *Proc Natl Acad Sci U S A* **103**:12729-12734.
- Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM and Shichida Y (2002) Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. *Proc Natl Acad Sci U S A* **99**:5982-5987.
- Okada T, Sugihara M, Bondar AN, Elstner M, Entel P and Buss V (2004) The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. *J Mol Biol* **342**:571-583.
- Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M and Miyano M (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. *Science* **289**:739-745.
- Parrill AL, Wang D, Bautista DL, Van Brocklyn JR, Lorincz Z, Fischer DJ, Baker DL, Liliom K, Spiegel S and Tigyi G (2000) Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. *J Biol Chem* **275**:39379-39384.
- Pyne S and Pyne N (2000) Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. *Pharmacol Ther* **88**:115-131.
- Renzetti AR, Catalioto RM, Criscuoli M, Cucchi P, Ferrer C, Giolitti A, Guelfi M, Rotondaro L, Warner FJ and Maggi CA (1999) Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor. *J Pharmacol Exp Ther* **290**:487-495.
- Salom D, Lodowski DT, Stenkamp RE, Le Trong I, Golczak M, Jastrzebska B, Harris T, Ballesteros JA and Palczewski K (2006) Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. *Proc Natl Acad Sci U S A* **103**:16123-16128.
- Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N and Rosen H (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. *J Biol Chem* **279**:13839-13848.
- Shin N, Coates E, Murgolo NJ, Morse KL, Bayne M, Strader CD and Monsma FJ, Jr. (2002) Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. *Mol Pharmacol* **62**:38-47.
- Spalding TA, Burstein ES, Henderson SC, Ducote KR and Brann MR (1998) Identification of a ligand-dependent switch within a muscarinic receptor. *J Biol Chem* **273**:21563-21568.
- Spiegel S and Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. *Nat Rev Mol Cell Biol* **4**:397-407.
- Tawadrous MN, Mabuchi A, Zimmermann A and Wheatley AM (2002) Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. *Transplantation* **74**:602-610.
- Teller DC, Okada T, Behnke CA, Palczewski K and Stenkamp RE (2001) Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). *Biochemistry* **40**:7761-7772.
- Thompson JD, Higgins DG and Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* **22**:4673-4680.
- van Rhee AM and Jacobson KA (1996) Molecular architecture of G protein-coupled receptors. *Drug Development Research* **37**:1-38.

MOL# 29223

- Wang DA, Lorincz Z, Bautista DL, Liliom K, Tigyi G and Parrill AL (2001) A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. *J Biol Chem* **276**:49213-49220.
- Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ and Rosen H (2003) Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. *J Immunol* **170**:3662-3670.

MOL# 29223

Footnotes

¹To whom correspondence may be addressed: Tel: 732-594-5787, Fax: 732-594-1399, E-mail: steve_parent@merck.com

²Current address: 78 Wertsville Road, Hillsborough, NJ 08844

³After submission of the manuscript, the authors note the recent release of X-ray crystal structures of activated forms of rhodopsin, including bathorhodopsin (PDB entry 2G87) (Nakamichi and Okada, 2006a), lumirhodopsin (PDB entry 2HPY) (Nakamichi and Okada, 2006b) and a photoactivated deprotonated intermediate of rhodopsin (PDB entry 2I37) (Salom et al., 2006). Given the high structural similarities between bovine rhodopsin in the dark state and the activated forms, the use of the dark state rhodopsin (1F88) as a modeling template would appear to be a reasonable starting point for homology modeling of family A GPCRs bound to agonists and antagonists.

MOL# 29223

Legends for Figures

Fig. 1. **The chemical structures of S1P, FTY720, FTY720-P and compounds A and B.**

Fig. 2. **Alignment of amino acid sequences of TM3, TM4, TM5, TM6 and TM7 in the S1P receptors with bovine rhodopsin.** Conserved residues are shown in black boxes. The most conserved residues in each helix are marked by an arrow and labeled with the Ballesteros-Weinstein index. Residues that are also conserved in the TM helices of rhodopsin are also shaded in black. Asterisks above the alignments denote residues predicted to be located within 4Å of ligand in the docking models of S1P₁ with S1P, FTY720-P, compounds A or B.

Fig. 3. **Docking model of S1P₁ in complex with FTY720-P.** (A) The TM structures of S1P₁ are shown as grey ribbons with residues located within 4 Å of the agonist highlighted in green and Leu276(6.55) highlighted in yellow. FTY720-P is shown in a spheres model, with carbon in purple, oxygen in red, nitrogen in blue and phosphorus in orange. The hydrogen atoms are omitted for clarity. (B) A perpendicular view of the TM helices of S1P₁ in complex with FTY720-P. The loop regions and the cytoplasmic helix were removed for clarity. The TM helices are shown as grey ribbons with residues located within 4Å of ligand highlighted in green and Leu276(6.55) highlighted in yellow. The side chains of Arg120 (3.28) and Glu121(3.29) are shown in stick form with carbon atoms in green, oxygen atoms in red and nitrogen atoms in blue. Leu276(6.55) is shown in stick form in yellow. The pictures were prepared by PyMOL (DeLano Scientific LLC, South San Francisco, CA).

Fig. 4. **A closer look at agonists in the S1P₁ binding site.** Agonists are shown in stick form with carbons in (A) S1P in yellow; (B) FTY720-P in purple; (C) compound A in cyan; (D) compound B in green. Hydrogen atoms are omitted for clarity. Six aromatic residues and Leu276 (6.55) in the binding pocket of S1P₁ receptor are shown as grey sticks. For comparison, a Phe residue is depicted in black and

MOL# 29223

overlaid onto the Leu276(6.55) of S1P₁ to model Phe263(6.55) in S1P₃. Oxygen atoms are depicted in red, nitrogen atoms in blue and phosphorous atoms in orange. The dashed lines illustrate atom pairs within hydrogen bond distance, indicating favorable interactions between the head group of the agonists and the charged residues Arg120(3.28) and Glu121(3.29) on TM3. The pictures were prepared by PyMOL (DeLano Scientific LLC, South San Francisco, CA).

Fig. 5. The S1P₁Leu276Phe and S1P₁ Phe263Leu mutations specifically alter the affinity of the S1P₁ and S1P₃ receptors for compound A. (A) Data are from a representative competitive binding experiment with CHO cells transiently transfected with the wild type or mutant S1P₁ receptors. Results (mean $\pm$ range, N=2) are from duplicate determinations in a single experiment and are plotted as the Fraction of Control Binding versus the logarithm of the concentration of the competitor. Similar agonist affinities were seen in several experiments. (B) Data are from a representative competitive binding experiment with CHO cells transiently transfected with the wild type or mutant S1P₃ receptors. Results (mean $\pm$ range, N=2) are from duplicate determinations in a single experiment and are plotted as the Fraction of Control Binding versus the logarithm of the concentration of the competitor. Similar agonist affinities were seen in several experiments.

Fig. 6. Expression of the S1P₁ Leu276Phe and S1P₃ Phe263Leu receptors. (A) Western hybridization analysis of wild type and mutant S1P₁ and S1P₃ receptors expressed in stable CHO cell lines with S1P₁ antiserum. The following amounts of membrane protein were eletrophoresed on the gel: 1 μ g of S1P₁; 0.2 μ g of S1P₁ Leu276Phe; 1 μ g of S1P₃; 1 μ g of S1P₃ Phe263Leu; 1 μ g of CHO control membrane protein. (B) Western hybridization analysis of wild type and mutant S1P₁ and S1P₃ receptors expressed in stable CHO cell lines with S1P₃ antiserum. The following amounts of membrane protein were electrophoresed: 4 μ g of S1P₁; 1 μ g of S1P₁ Leu276Phe; 1 μ g of S1P₃; 1 μ g of S1P₃ Phe263Leu; 1 μ g of CHO control membrane protein.

MOL# 29223

Fig. 7. Localization of the S1P₁ Leu276Phe and S1P₃ Phe263Leu receptors. Stable CHO cell lines expressing the wild type or mutant S1P₁ and S1P₃ receptors were prepared for immunohistochemistry and confocal microscopy as described in the Materials and Methods. Panels on the left show cells treated with the S1P₁ antiserum. Panels on the right show cells treated with the S1P₃ antiserum. The upper panels show control CHO cells transfected with a vector plasmid.

Fig. 8. The S1P₁ Leu276Phe and S1P₃ Phe263Leu mutations specifically alter the agonist potencies of compounds A and B. Data are from GTP γ S binding experiments with membrane protein prepared from the stable cell lines expressing the wild type or mutant S1P receptors. Results (mean $\pm$ S.E) are from three experiments performed in triplicate and are plotted as the Percent Basal Activity versus the logarithm of the agonist concentration. (A) S1P₁ receptor, basal activity = 1102 $\pm$ 137 fmoles/mg; (B) S1P₁ Leu276Phe mutant receptor, basal activity = 862 $\pm$ 51 fmoles/mg; (C) S1P₃ receptor, basal activity = 1555 $\pm$ 73 fmoles/mg; (D) S1P₃ Phe263Leu mutant receptor, basal activity = 2065 $\pm$ 50 fmoles/mg.

MOL# 29223

Table 1. Effects of Leu276Phe and Phe263Leu point mutations on the binding of S1P to the S1P₁ and S1P₃ receptors

Receptor	K_d (nM)	$B_{\max}$ (fmol/ μ g)
S1P ₁	0.39 ± 0.04	9.26 ± 0.08
S1P ₁ Leu276Phe	0.29 ± 0.01	13.89 ± 0.33
S1P ₃	0.23 ± 0.08	14.24 ± 1.78
S1P ₃ Phe263Leu	0.22 ± 0.04	15.98 ± 1.40

K_d and $B_{\max}$ were determined in saturation binding assays with ³³P-S1P (3000 Ci/mmol) as described in the Materials and Methods. Data were analyzed by nonlinear regression and fit to a one site binding model using the program Prism (GraphPad Software, San Diego, CA). Results are expressed as the mean $\pm$ range of two experiments performed in triplicate.

MOL# 29223

Table 2: The effects of the S1P₁ Leu276Phe and S1P₃ Phe263Leu mutations on affinities of S1P, FTY720-P, compound A and compound B

Compound	Log IC ₅₀ (M)			
	S1P ₁	S1P ₁ L276F	S1P ₃	S1P ₃ F263L
S1P	-9.20 ± 0.22	-9.29 ± 0.16	-9.35 ± 0.15	-9.29 ± 0.17
FTY720-P	-8.96 ± 0.08	-8.88 ± 0.04	-8.57 ± 0.19	-8.41 ± 0.13
Compound A	-8.49 ± 0.19	-7.37 ± 0.08 [*]	-5.73 ± 0.15	-6.71 ± 0.03 [§]
Compound B	-8.93 ± 0.04	-7.33 ± 0.05 [¶]	-5.38 ± 0.15	-7.56 ± 0.05 [†]

Compound affinities (Log IC₅₀) were calculated from ³³P-S1P binding dose response curves. Results are expressed as the mean ± S.E. of three experiments performed in triplicate. The following symbols denotes values that are significantly different from wild type: [§]*P* = 0.0028; ^{*}*P* = 0.0055; [†]*P* = 0.0002; [¶]*P* = <0.0001

MOL# 29223

Table 3: Effects of the S1P₁ Leu276Phe and S1P₃ Phe263Leu mutations on agonist activities of S1P, FTY720-P, compound A and compound B

	S1P		FTY720-P		Compound A		Compound B	
	Log EC ₅₀	E _{max} [*]	Log EC ₅₀	E _{max} [*]	Log EC ₅₀	E _{max} [*]	Log EC ₅₀	E _{max} [*]
	(M)	%	(M)	%	(M)	%	(M)	%
S1P ₁	-7.48 ± 0.13	100	-9.54 ± 0.15	95	-8.81 ± 0.16	93	-9.61 ± 0.20	98
S1P ₁ L276F	-7.58 ± 0.10	115	-8.76 ± 0.06 [§]	109	-6.90 ± 0.08 [¶]	103	-6.66 ± 0.09 [*]	116
S1P ₃	-8.45 ± 0.09	100	-8.87 ± 0.08	106	-6.34 ± 0.07	104	-5.85 ± 0.08	128
S1P ₃ F263L	-8.64 ± 0.13	82	-9.07 ± 0.10	93	-7.97 ± 0.10 [*]	85	-8.98 ± 0.16 [†]	80

Agonist potencies (Log EC₅₀) were calculated from GTPγS binding dose response curves. Results are expressed as mean ± S.E. of three experiments performed in triplicate. *The efficacies (E_{max}) of the agonists tested to stimulate GTPγS binding are expressed as the percentage of the maximal increase obtained with 5 μM S1P on the wild type S1P₁ or S1P₃ receptor. The following symbols denote values that are significantly different from wild type: [§]P = 0.0083; [¶]P = 0.0004; ^{*}P = 0.0002; [†]P < 0.0001.

Figure 1

Figure 2

Figure 3

A.

B.

Figure 4

A.

B.

C.

D.

A.

B.

Figure 6

A.

B.

Figure 7

Figure 8